Global Statistics

spot_img

Peter Hofland

At the helm of Sunvalley Communication, I lead initiatives that bridge medical expertise with journalistic integrity, specializing in oncology, hematology, and (general) pharmaceutical reporting. In collaboration with my team, I craft compelling narratives that inform healthcare professionals and the public, leveraging over 18 years of industry insight.
Author's Latest

SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer

During the Society of Immunotherapy of Cancer (SITC) 2025 Annual Meeting, held November 5 – 9 at the Gaylord National Resort and Convention Center in...

Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy

In early November, a team of physicians at Jiahui International Cancer Center (JICC), part of Jiahui International Hospital, Shanghai's first large-scale international tertiary hospital,...

Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia

One of the most common cancers in children, leukemia, may have met its match. Scientists at Roswell Park Comprehensive Cancer Center are at the...

Verismo Therapeutics to Present Updated Study Results at SITC and ASH

During the upcoming Society of Immunotherapy in Cancer (SITC) 2025 Annual Meeting, held November 7-9, 2025, and during the American Society of Hematology (ASH)...

Loma Linda University Health awarded $9 million from the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine (CIRM) has awarded $9 million to Loma Linda University Health  to create a Community Care Center of Excellence (CCCE) in...

STAR-101 Study results Highlighted at the 17th International Mesothelioma Interest Group (iMig) 2025

Results from the first-in-humans (FIH) STAR-101 clinical study (NCT05568680), an ongoing, open-label multicenter Phase 1 clinical trial designed to evaluate the safety, feasibility, and...

Emily Whitehead Foundation to Expands its Mission Beyond Pediatric Cancer

The Emily Whitehead Foundation, established by Tom and Kari Whitehead, the parents of Emily Whitehead, the first pediatric patient to receive life-saving CAR T-cell...

Verismo Therapeutics to Partner with Miltenyi Biotec to Support Advancing Clinical Programs

Verismo Therapeutics, a subsidiary of HLB Innovation developing CAR T-Cell Therapies based on the company's novel KIR-CAR platform technology,* confirmed the successful manufacture of...

Lumicks’ Avidion Launched to Improves Cell Therapy Development

During the Ninth International Cancer Immunotherapy Conference, CICON25, taking place September 10-12, 2025, in Utrecht, The Netherlands, Lumicks, a pioneering life science tools company,...

Missing Messenger RNA Fragments Could be the Key to a New Immunotherapy for Hard-to-Treat Tumors

A new study, led by researchers at the Children's Hospital of Philadelphia (CHOP), identified tiny messenger RNA fragments that are absent in pediatric high-grade...

Novel CAR T-Cell Therapy for Neuroendocrine Cancer Receives FDA Fast Track Designation

CHM-2101, an autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR-) T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or...

ASCO 2025: Satricabtagene Autoleucel Significantly Improves PFS and OS in advanced Gastric or Gastroesophageal Junction Carcinoma

Satricabtagene autoleucel (CT041; satri-cel; CARsgen Therapeutics), an autologous chimeric antigen receptor (CAR) T-cell product candidate against protein Claudin18.2, improves progression-free survival (PFS) and overall...

Survey: Majority of Americans are Unaware of Groundbreaking Treatment option for Blood Cancer

Researchers at Roswell Park Comprehensive Cancer Center are at the forefront of a new approach to cancer treatment, called chimeric antigen receptor (CAR) T-cell...

ESMO 2021: CT041, A New CAR-T for the Treatment of in Advanced Gastric Cancer

Each year, approximately one million new cases of gastric cancer, diseases of malignant glandular cells, are diagnosed worldwide. And despite recent advances in treatment...

- A word from our sponsors -

spot_img

Follow us

HomeAuthorsPosts by Peter Hofland

The Journal of CAR T-Cell Therapy is an international science & medicine-focused news publication designed to serve the needs of a diverse community, including academia, life sciences, pharma, clinical research, clinicians, and physicians. Along with global clinical and regulatory news, we also cover payor and policy-related news and updates.

© Copyright 2025, 2026 Sunvalley Communication, LLC and AAMEI®, American Association for Medical Education and Information - All Rights Reserved.

Quick Links

Must Read

Popular Articles